I am a healthcare professional

Notice

Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.

Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.

By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.

Cookies

We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.

You can find out more about cookies by browsing our Privacy Policy.

I am a healthcare professional in the United States

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Roche and Genentech at

Joint ACTRIMS-ECTRIMS meeting: MSToronto 2026

October 21 - October 23

Toronto, Canada / Virtual (Hybrid)

mstoronto2026.org

We will be contributing to topics related to

Neuroscience

Agenda

Medical Materials

01:00 PM

Duration 60mins Toronto, Canada

Impact of Ocrelizumab on Work Productivity, Healthcare Use and Caregiver Burden in Relapsing Multiple Sclerosis: Final Analysis of the MuSicalE Study

Maria Trojano, Vincent van Pesch, Raed Alroughani,Àlex Rovira, Gary Cutter, Athanasios Siadimas, Rakesh Kantaria, Licinio Craveiro, Sebastian Camerlingo, Jeremy Hobart

Neuroscience | Multiple Sclerosis

Duration 60mins Toronto, Canada

Real-world treatment patterns and persistence with subcutaneous ocrelizumab in Denmark, Germany, and the United Kingdom

Melinda Magyari, Stefan Braune,Gillian Ingram, Finn Sellebjerg, Jeppe Romme Christensen, Peter Vestergaard Rasmussen, Henrik Boye Jensen, Sivagini Prakash, Morten Rytgaard, Arnfin Bergmann, James Witts, Owen R Pearson, Rod Middleton, Jana B. Jarecki, Yanic Heer, Ana Ferro, Sebastian Camerlingo, NTD Study group,

Neuroscience | Multiple Sclerosis

Duration 60mins Toronto, Canada

Shorter Outpatient Visit Times for Patients With MS Treated With Subcutaneous Ocrelizumab Compared With Infused Anti-CD20 Disease-Modifying Therapies: A Retrospective Analysis of Electronic Health Records in the US

Kavita V. Nair, Arpamas Seetasith, Karina Raimundo, Katherine Brown, Mantas Dmukauskas, Megan Fiasconaro, Grace Leung

Neuroscience | Multiple Sclerosis

Duration 60mins Toronto, Canada

A Phase II, Open-Label, Single-Arm Trial to Evaluate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (FENerations1): Study Design and Baseline Characteristics

Kumaran Deiva, Henry Sato, Katarzyna Kotulska, Geoff Powell, Yan Xu, Fei Tang, Ke Yang, Jon Lopez, Nisha Shah, Marina Ziehn, Ying-Fang Chen

Neuroscience | Multiple Sclerosis

06:50 PM

Duration 10mins Toronto, Canada

Efficacy of Fenebrutinib vs Teriflunomide in Relapsing Multiple Sclerosis: Pooled Analysis Results From the FENhance 1 and 2 Studies

Maria Pia Sormani, Paul S. Giacomini, Mateus Boaventura, Fu-Dong Shi, Annette Okai, Ahmed Z. Obeidat, Finn Sellebjerg, Marquita Decker-Palmer, Anastasia Loukitcheva, Lilyan Wright, Nan Hu, Yoonha Choi, Katrin Madjar, Ann E. Herman, Christopher Harp

Neuroscience | Multiple Sclerosis

08:30 PM

Duration 120mins Toronto, Canada

MuSicalE: Prognostic Value of Patient-Reported Outcomes in Predicting Ocrelizumab Discontinuation and Preservation of Clinical Status

Gary Cutter, Sebastian Camerlingo, Maria Trojano, Vincent van Pesch, Raed Alroughani, Àlex Rovira, Rakesh Kantaria, Licinio Craveiro, Jeremy Hobart

Neuroscience | Multiple Sclerosis

Duration 120mins Toronto, Canada

B-Cell Reconstitution and Changes in Serum Neurofilament Light Chain During Pregnancy and Post Partum in Women Who Received Ocrelizumab: Results From the Prospective Phase IV MINORE Study

Riley Bove, Sandra Vukusic, Ruth Dobson, Kerstin Hellwig, Thomas F. McElrath, Celia Oreja-Guevara, Carlo Pietrasanta, Jens Kuhle, Agne Kazlauskaite, Licinio Craveiro, Chien-Ju Lin, Catarina Raposo, Noemi Pasquarelli, Tobias J. Derfuss

Neuroscience | Multiple Sclerosis

10:30 PM

Duration 120mins Toronto, Canada

Longitudinal Analysis of Clinical Characteristics and Decision Drivers of Untreated People With Multiple Sclerosis in the German NeuroTransData (NTD) Real World Registry (2018–2024)

Stefan Braune, Yanic Heer, Carmen G. Berardo, Ana Ferro, Arnfin Bergmann, Juan Acosta, NTD Study Group, Martin Traber

Neuroscience | Multiple Sclerosis

Duration 120mins Toronto, Canada

Real-World Effectiveness and Safety of First-Line Ocrelizumab Treatment in Early-Stage Relapsing Multiple Sclerosis

Tim Spelman, Raed Alroughani, Allan Kermode, Mario Habek, Tomas Kalincik, Dana Horakova, Anneke van Der Walt, William Brown, Gregor Brecl Jakob, Seyedmohammad Baghbanian, Serkan Ozakbas, Jeannette Lechner Scott, Radek Ampapa, Matteo Foschi, Cavit Boz, Julie Prévost, O. Gerlach, Simón Cárdenas-Robledo, Jose E Meca-Lallan, Emanuele D'amico, Richard MacDonell, Guy Laureys, Michael Barnett, Abdorreza Naser Moghadasi, Pamela McCombe, Juan Ignacio Rojas, Nevin A John, Nikolaos Grigoriadis, Davide Maimone, Inés González-Suárez, Yi Chao Foong, Katherine Buzzard, Beatriz Romero Ferrando, Mehmet Yetkin, Sara Eichau, Bassem Yammout, Ana Ferro, Erwan Muros-Le Rouzic, Licinio Craveiro, Helmut Butzkueven

Neuroscience | Multiple Sclerosis

Duration 120mins Toronto, Canada

Plasma Cells, Myeloid, and Endothelial Cells At or Near Chronic Active Lesions Express MS Severity GWAS Genes Indicating Association with Progressive Biology

Tanuja Chitnis, Kalani Ratnasiri, Devin King, Alfredo Morales-Pinzon, Nicolas Strauli, Danielle Caefer, Michele Cavallari, Kyle C. Downer, Ethan Goodman, Aaron Grant, Ann Herman, Rihao Qu, Luke Xie, Jeffrey Hofmann, Tushar Bhangale, Akshaya Ramesh, Charles R.G. Guttmann, Xiaoming Jia

Neuroscience | Multiple Sclerosis

08:30 PM

Duration 120mins Toronto, Canada

Impact of Ocrelizumab vs Fingolimod on Immune Function in Pediatric Patients With MS in the OPERETTA 2 Study

Amit Bar-Or, Barbara Kornek, Brenda Banwell, Chien-Ju Lin, Corinne Manlius, Fabien Bakdache, Filipe Palavra, Katarzyna Kotulska-Jozwiak, Kumaran Deiva, Liudmila Gearhart, Tammy Hennika, Tanuja Chitnis, Yun-An Shen

Neuroscience | Multiple Sclerosis

Duration 120mins Toronto, Canada

Levels of Circulating B Cells and B Cell Subsets During Ocrelizumab Treatment in the CHIMES Trial of Black and Hispanic People With Multiple Sclerosis

Gregory Wu, Anne Cross, Anthony Reder, Craig Herrman, Ellen Mowry, Evanthia Bernitsas, Ibraheem Abioye, Jinglan Pei, Jugena Ndrio, Juzar Hooker, Kiel Telesford, Lilyana Amezcua, Mansoor Saleh, Mitzi Williams, Nancy Monson, Siddharama Pawate

Neuroscience | Multiple Sclerosis

Duration 120mins Toronto, Canada

Vaccination and Disease-Modifying Therapies: Impact of Ocrelizumab vs Fingolimod on Preexisting Vaccine Seropositivity and Vaccine-Preventable Infections in Pediatric Patients With MS in OPERETTA 2

Brenda Banwell, Amit Bar-Or, Barbara Kornek, Chien-Ju Lin, Corinne Manlius, Fabien Bakdache, Filipe Palavra, Katarzyna Kotulska-Jozwiak, Kumaran Deiva, Liudmila Gearhart, Tammy Hennika, Tanuja Chitnis, Yun-An Shen

Neuroscience | Multiple Sclerosis

Duration 120mins Toronto, Canada

OPERETTA 2: Continued Follow-Up of the Efficacy and Safety Profile of Ocrelizumab in Pediatric Relapsing-Remitting MS

Kumaran Deiva, Barbara Steinborn, Brenda Banwell, Carole Marcillat, Chien-Ju Lin, Corinne Manlius, Eduardo Vasconcellos, Leslie Benson, Miao Xu, Rafael Paterno, Romain Marignier, Tammy Hennika, Teri Schreiner, Tetyana Nehrych

Neuroscience | Multiple Sclerosis

Duration 120mins Toronto, Canada

Long-Term Impact of First-Line Ocrelizumab Treatment in Early-Stage Relapsing-Remitting Multiple Sclerosis: Results From the 6-Year Phase III ENSEMBLE-LIBERTO Study

Robert A. Bermel, Gary R. Cutter, Rana Karabudak, Mark S. Freedman, Francesco Patti, Bruno Brochet, Ludo Vanopdenbosch, Ralph H.B. Benedict, Hans-Peter Hartung, Yuliang He, Héctor Lorenzo,Fabien Bakdache, Vanessa Di Felice, Licinio Craveiro, Joep Killestein

Neuroscience | Multiple Sclerosis

Duration 120mins Toronto, Canada

Ocrelizumab Maintains Clinical and Safety Outcomes in Older Patients (>55 Years) With Progressive Multiple Sclerosis: 2-Year Results From the CONSONANCE Study

Helmut Butzkueven, Douglas Arnold, Amit Bar-Or, Ralph Benedict,Robert Bermel, Pavan Bhargava, Kathleen Blondeau, Declan Chard, Licinio Craveiro, Roland G. Henry, Owain Howell, Letizia Leocani, Marisa P. McGinley, Xavier Montalban, Finn Sellebjerg, Maria P.Sormani, Agne Kazlauskaite,Christine Lebrun-Frenay

Neuroscience | Multiple Sclerosis

Duration 120mins Toronto, Canada

Comparing Serum Immunoglobulin G Trajectories Between Ocrelizumab and Ofatumumab: Real-World Evidence From a German Multiple Sclerosis Cohort

Stefan Braune, Niloofar Tavakoli, Inga Umbetova, Oliver Fasold, Johannes Fischer, Ralf Jankovits, Boris Kallmann, Thomas Knoll, Peter Kraft, Jürgen Kunz, Klaus Lehmann-Horn, Said Masri, Robert Pfister, Martin A. Schaller-Paule, Arnfin Bergmann, NTD Study Group, Yanic Heer, Mel Zuercher, Erwan Muros-Le Rouzic, Licinio Craveiro

Neuroscience | Multiple Sclerosis

Duration 120mins Toronto, Canada

Sex Differences in Disease-Modifying Therapy Exposure Among Menopausal-Aged Adults With MS

Riley Bove, Divya Jain, Rongrong Wang, Noemi Pasquarelli, Erwan Muros-Le Rouzic, Arpamas Seetasith, Elmor D. Pineda

Neuroscience | Multiple Sclerosis

Duration 120mins Toronto, Canada

No Evidence of Disease Activity With Fenebrutinib vs Teriflunomide in Relapsing Multiple Sclerosis: Results From the Phase III FENhance 1 and 2 Trials

João José Fernandes Cardoso Araújo Cerqueira, Jelena Drulovic, Christine Lebrun-Frenay, Tjalf Ziemssen, Marquita Decker-Palmer, Anastasia Loukitcheva, Stephanie Son, Claude Berge, Katrin Madjar, Nicolas Lindau, Monika Adamczyk-Sowa

Neuroscience | Multiple Sclerosis

Duration 120mins Toronto, Canada

Fenebrutinib Reduces CSF Microglial and Astrocyte Biomarkers Expressed at or Near Chronic Active Rim Lesions in Patients With RMS or PPMS

Amit Bar-Or, Christopher Harp, Jenny Jiang, Katrin Madjar, Enrique Alvarez, João Cerqueira, Rebecca S. Farber, Freddy Guillermo Castro Farfán, Ho Jin Kim, Enric Monreal, Luisa María Villar, Martin S. Weber, Esther Nie, Shristi Pandey, Dwight F. Newton, Xiaoming Jia, Akshaya Ramesh, Ann E. Herman, Finn Sellebjerg

Neuroscience | Multiple Sclerosis

Duration 60mins Toronto, Canada

Quality of shared decision-making in early relapsing-remitting multiple sclerosis: results from the AGA-25 questionnaire

Inés González-Suárez, Elena García-Arcelay, Jacobo Caruncho, Antonio Candeliere-Merlicco, Aida Orviz, Jesús Martín-Martínez, Raquel Piñar, Elena Álvarez-Rodríguez, Eva Pacheco, Laura Borrega, Ignacio Casanova, Ana B Caminero, José L Sánchez-Menoyo, Montserrat Gómez-Gutiérrez, Olga Carmona, Carmen Calles, Miguel A Hernández, Pablo López-Muñoz, Jorge Mauriño, Ángel Pérez-Sempere

Neuroscience | Multiple Sclerosis

Duration 120mins Toronto, Canada

Predictors of High Fear of Relapse in Patients with Early- Stage Relapsing-Remitting Multiple Sclerosis

Ángel Pérez-Sempere, Elena García-Arcelay, Jacobo Caruncho, Antonio Candeliere-Merlicco, Aida Orviz, Jesús Martín-Martínez, Raquel Piñar, Elena Álvarez-Rodríguez, Eva Pacheco, Laura Borrega, Ignacio Casanova, Ana B Caminero, José L Sánchez-Menoyo, Montserrat Gómez-Gutiérrez, Olga Carmona, Carmen Calles, Miguel A Hernández, Pablo López-Muñoz, Jorge Mauriño, Inés González-Suárez

Neuroscience | Multiple Sclerosis

03:05 PM

Duration 10mins Toronto, Canada

Fenebrutinib Shows a Therapeutic Effect on MS Progressive Biology: Outcomes on Paramagnetic Rim Lesions and Slowly Expanding Lesions in the Phase III FENhance I/II and FENtrepid Trials in Relapsing and Primary Progressive Multiple Sclerosis

Jiwon Oh, Robert Carruthers, Olga Shulga, Robert T. Naismith, Douglas L. Arnold, Dan Ontaneda, Esther Nie, Louise Roberts, Jon Lopez, Nan Hu, Katrin Madjar, David Clayton, Finn Sellebjerg

Neuroscience | Multiple Sclerosis

Coming soon